Abstract
Epilepsy is characterized by repeated seizure activity. Valproate, acommonly used antiepilepticdrug, shows large inter-individual variation in plasma valproic levels and causes many adverse drug reactions. Aim: To find the influence of CYP2C9*2 and *3 polymorphisms on valproate-associated adverse drug reactions and plasma valproic acid levelsin people with epilepsy. Methods: We recruited 158 peoplewith epilepsy(79 cases and 79 controls) from anepilepsy clinic. Steady-state plasma valproic acid levels were measured using liquid chromatography-mass spectrometryand genotyping of CYP2C9 variantswas carried out with helps of RT-PCR. Results: The presence of a mutantheterozygousgenotype showed an odds ratio (OR) of 2.82 (95% CI: 1.10-7.24) andthe adjusted OR was 5.39 (95% CI: 1.69-17.16). There was no significant difference in steady-state plasma valproate concentration between genotypes. Conclusion: The presence of amutant heterozygous CYP2C9 genotype possesses five-times the risk of developing adverse drug reactions to valproate in people with epilepsy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
